BN Business News
添加企业 →
本文翻译正在准备中。在此之前,我们暂时显示英文原文。

监管与法律 · 1995/8/291 分钟阅读

Cold, Cough, Allergy, Bronchodilator, and Antiasthmatic Drug Products for Over-the-Counter Human Use; Proposed Amendment of Monograph for OTC Bronchodilator Drug Products; Extension of Comment Period

本地自动翻译 · 来源原始语言

摘要

The Food and Drug Administration (FDA) is extending to September 27, 1995, the period for comments for the notice of proposed rulemaking to amend the monograph for over-the-counter (OTC) bronchodilator drug products that was published in the Federal Register of July 27, 1995. That document proposed to remove the ingredients ephedrine, ephedrine hydrochloride, ephedrine sulfate, and racephedrine hydrochloride from the final monograph for OTC bronchodilator drug products and to classify these ingredients as not generally recognized as safe and effective for OTC use. FDA is taking this action in response to several requests to extend the period for comments to allow interested persons adequate time to assess and respond to the proposal.

来源原始语言: Federal Register — All Documents打开原始公告 →

探索专题

商业洞察 →